{"groups":[{"description":"Participants received sacituzumab govitecan-hziy (SG) 8 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.","id":"FG000","title":"Sacituzumab Govitecan-hziy (SG) 8 mg/kg"},{"description":"Participants received sacituzumab govitecan-hziy 10 mg/kg of body weight via IV infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.","id":"FG001","title":"SG 10 mg/kg"},{"description":"Participants received sacituzumab govitecan-hziy 12 mg/kg of body weight via IV infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.","id":"FG002","title":"SG 12 mg/kg"},{"description":"Participants received sacituzumab govitecan-hziy 18 mg/kg of body weight via IV infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.","id":"FG003","title":"SG 18 mg/kg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"83"},{"groupId":"FG001","numSubjects":"420"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"81"},{"groupId":"FG001","numSubjects":"402"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"3"}],"type":"Enrolled and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"81"},{"groupId":"FG001","numSubjects":"400"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Tumor types included in the study were as follows: cervical, colorectal, endometrial, ovarian, esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell, small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast cancer (TNBC) and metastatic urothelial cancer (mUC).","recruitmentDetails":"Participants were enrolled at study sites in the United States. The first participant was screened on 17 December 2012. The last study visit occurred on 13 August 2020.\n\nOutcome Measures were assessed up to the data cutoff date of 01 March 2019. Following the data cutoff date, the participants either stayed on the study and were followed for safety data collection or rolled into another Gilead-sponsored study. Therefore, only safety data was collected after the data cutoff date."}